TransMedics Group (NASDAQ:TMDX) Shares Down 4.3% – Should You Sell?

TransMedics Group, Inc. (NASDAQ:TMDX) shares dropped 4.3% during mid-day trading on Wednesday . The company traded as low as $132.50 and last traded at $135.88. Approximately 314,255 shares were traded during mid-day trading, a decline of 54% from the average daily volume of 689,225 shares. The stock had previously closed at $141.93.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Jefferies Financial Group initiated coverage on TransMedics Group in a report on Monday, October 13th. They set a “buy” rating and a $145.00 price target on the stock. Zacks Research lowered shares of TransMedics Group from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Wall Street Zen raised shares of TransMedics Group from a “hold” rating to a “buy” rating in a research note on Sunday, December 28th. Piper Sandler reiterated an “overweight” rating on shares of TransMedics Group in a report on Monday, December 22nd. Finally, Canaccord Genuity Group increased their price objective on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Six analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, TransMedics Group currently has an average rating of “Moderate Buy” and a consensus price target of $144.25.

TransMedics Group Trading Down 5.0%

The firm has a market cap of $4.61 billion, a price-to-earnings ratio of 54.61 and a beta of 2.03. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13. The firm’s fifty day moving average is $131.69 and its 200-day moving average is $122.75.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.29. The firm had revenue of $143.82 million during the quarter, compared to analyst estimates of $145.33 million. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The business’s quarterly revenue was up 32.2% on a year-over-year basis. During the same period last year, the company posted $0.12 EPS. Equities analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Edward M. Basile sold 4,142 shares of the stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total transaction of $540,323.90. Following the transaction, the director directly owned 2,866 shares of the company’s stock, valued at $373,869.70. This represents a 59.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David Weill sold 5,000 shares of the firm’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total transaction of $693,200.00. Following the completion of the sale, the director owned 12,134 shares of the company’s stock, valued at $1,682,257.76. The trade was a 29.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 13,062 shares of company stock valued at $1,797,634 in the last ninety days. 7.00% of the stock is owned by corporate insiders.

Institutional Trading of TransMedics Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of TransMedics Group by 0.3% during the third quarter. Vanguard Group Inc. now owns 3,605,607 shares of the company’s stock valued at $404,549,000 after acquiring an additional 9,650 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in TransMedics Group by 11.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock valued at $119,997,000 after purchasing an additional 113,817 shares during the period. Geode Capital Management LLC increased its stake in TransMedics Group by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 804,650 shares of the company’s stock valued at $107,845,000 after purchasing an additional 11,241 shares in the last quarter. Two Sigma Investments LP raised its holdings in TransMedics Group by 54.2% during the third quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock worth $71,291,000 after buying an additional 223,409 shares during the last quarter. Finally, Marshall Wace LLP lifted its stake in shares of TransMedics Group by 258.7% in the second quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock valued at $73,275,000 after buying an additional 394,340 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.